| Title : Serum soluble CD26\/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody - Kaneko_2021_Biomark.Res_9_21 |
| Author(s) : Kaneko Y , Hatano R , Hirota N , Isambert N , Trillet-Lenoir V , You B , Alexandre J , Zalcman G , Valleix F , Podoll T , Umezawa Y , Takao S , Iwata S , Hosono O , Taguchi T , Yamada T , Dang NH , Ohnuma K , Angevin E , Morimoto C |
| Ref : Biomark Res , 9 :21 , 2021 |
| Abstract : Kaneko_2021_Biomark.Res_9_21 |
| ESTHER : Kaneko_2021_Biomark.Res_9_21 |
| PubMedSearch : Kaneko_2021_Biomark.Res_9_21 |
| PubMedID: 33757558 |
Kaneko Y, Hatano R, Hirota N, Isambert N, Trillet-Lenoir V, You B, Alexandre J, Zalcman G, Valleix F, Podoll T, Umezawa Y, Takao S, Iwata S, Hosono O, Taguchi T, Yamada T, Dang NH, Ohnuma K, Angevin E, Morimoto C (2021)
Serum soluble CD26\/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody
Biomark Res
9 :21
Kaneko Y, Hatano R, Hirota N, Isambert N, Trillet-Lenoir V, You B, Alexandre J, Zalcman G, Valleix F, Podoll T, Umezawa Y, Takao S, Iwata S, Hosono O, Taguchi T, Yamada T, Dang NH, Ohnuma K, Angevin E, Morimoto C (2021)
Biomark Res
9 :21